MSI2 and invasive breast carcinoma: Therefore, we first analyzed the expression of Musashi-2 across cancers, including colon adenocarcinoma (COAD), breast cancer (BRCA), esophageal cancer (ESCA), and lung adenocarcinoma (LUAD), etc (Figure 1A).